Loading...
•
Dec 31, 2020
BioCryst Q4 2020 Earnings Report
BioCryst's financial performance reflected increased R&D and SG&A expenses, driven by investment in key programs and the U.S. launch of ORLADEYO, while revenues decreased due to the absence of RAPIVAB sales and a milestone payment recognized in the previous year.
Key Takeaways
BioCryst Pharmaceuticals reported Q4 2020 financial results, featuring a revenue of $4.0 million, a net loss of $60.5 million, and increased R&D and SG&A expenses. The company highlighted the approvals of ORLADEYO in the U.S. and Japan, advancements in the BCX9930 program, and a strong cash position of $302.6 million.
ORLADEYO approved in the U.S. and Japan, with EU approval expected in Q2.
Dose-ranging trial of BCX9930 fully enrolled with data presentation planned for March 22.
Company secured $325 million in financing during Q4 2020, bolstering year-end cash reserves to $303 million.
Total revenues were $4.0 million, compared to $39.7 million in the fourth quarter of 2019.
Forward Guidance
BioCryst did not provide specific revenue or operating expense guidance for 2021. The company believes its current cash runway takes them into 2023 based on expectations for revenue, operating expenses, and the option to access an additional $75 million from its existing credit facility.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...